Tech Company Financing Transactions
Rubicon Genomics Funding Round
On 12/31/2007, Rubicon Genomics secured $5.9 million in funding from ARCH Development Partners and Duchossois Technology Partners.
Transaction Overview
Company Name
Announced On
12/31/2007
Transaction Type
Venture Equity
Amount
$5,907,000
Round
Undisclosed
Investors
ARCH Development Partners (Teri Willey)
Duchossois Technology Partners (Daniel Phelps)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4355 Varsity Dr.
Ann Arbor, MI 48108
USA
Ann Arbor, MI 48108
USA
Phone
Website
Email Address
Overview
Rubicon has developed a superior test to non-invasively diagnose cancer and other diseases using its proprietary MethylPlex technology to amplify the exceedingly small amounts of abnormally-methylated DNA that are released by diseased tissue into serum and urine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Koziarz
Chief Scientific Officer
John Langmore
General Manager
Christine Haakenson
VP - Manufacturing
Takao Kurihara
VP - R & D
Emmanuel Kamberov
Browse more venture capital transactions:
Prev: 12/31/2007: Zafgen venture capital transaction
Next: 12/31/2007: Cine-tal Systems venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs